Karim Amrane

Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19)

Astrid Lièvre, Anthony Turpin, Isabelle Ray‐Coquard et al. · European Journal of Cancer · 2020 · 164 citations · Full text

Medicine, Infectious Diseases, Oncology +14

Lung cancer trends and tumor characteristic changes over 20 years (2000–2020): Results of three French consecutive nationwide prospective cohorts’ studies

D. Debieuvre, Olivier Molinier, L. Falchero et al. · The Lancet Regional Health - Europe · 2022 · 76 citations · Full text

Medicine, Oncology, Cancer Epidemiology +16

First‐line pembrolizumab for non–small cell lung cancer patients with PD‐L1 ≥50% in a multicenter real‐life cohort: The PEMBREIZH study

Karim Amrane, Margaux Geier, R. Corre et al. · Cancer Medicine · 2020 · 64 citations · Full text

Medicine, Oncology, Pharmacology +17

Prediction of response to immune checkpoint inhibitor therapy using 18F-FDG PET/CT in patients with melanoma

Karim Amrane, D. Le Goupil, Gilles Quéré et al. · Medicine · 2019 · 34 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

First-line single-agent pembrolizumab for PD-L1-positive (tumor proportion score ≥ 50%) advanced non-small cell lung cancer in the real world: impact in brain metastasis: a national French multicentric cohort (ESCKEYP GFPC study)

R. Descourt, Laurent Greillier, M. Pérol et al. · Cancer Immunology Immunotherapy · 2022 · 27 citations · Full text

Medicine, Oncology, Pharmacology +17